Serum Cytokine Profiles Associated with Specific Adjuvants Used in a DNA Prime-Protein Boost Vaccination Strategy

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Buglione Corbett, Rachel ^a   Pouliot, Kimberly ^a   Marty Roix, Robyn ^a   West, Kim ^a   Wang, Shixia ^a   Lien, Egil ^a   Lu, Shan ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CHEMOKINE; CYTOKINE; DNA VACCINE; DP 6 001; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; QS 21; RECOMBINANT GP120 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SAFETY; FEMALE; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES; VACCINES, DNA;

EID: 84883380519     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074820     Document Type: Article

References (47)

1. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, et al. (2012) The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 188: 5166-5176. doi:10.4049/jimmunol.1102756. PubMed: 22529301.
2. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, et al. (2012) Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206: 431-441. doi:10.1093/infdis/jis367. PubMed: 22634875.
3. Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, et al. (2011) Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLOS ONE 6: e27837. doi:10.1371/journal.pone.0027837. PubMed: 22205930.
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220. doi:10.1056/NEJMoa0908492. PubMed: 19843557.
5. Bansal A, Jackson B, West K, Wang S, Lu S, et al. (2008) Multifunctional T-Cell Characteristics Induced by a Polyvalent DNA Prime/Protein Boost Human Immunodeficiency Virus Type 1 Vaccine Regimen Given to Healthy Adults Are Dependent on the Route and Dose of Administration. J Virol 82: 6458-6469. doi:10.1128/JVI.00068-08. PubMed: 18448544.
6. Kennedy JS, Co M, Green S, Longtine K, Longtine J, et al. (2008) The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 26: 4420-4424. doi:10.1016/j.vaccine.2008.05.090. PubMed: 18588934.
7. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, et al. (2008) Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26: 1098-1110. doi:10.1016/j.vaccine.2007.12.024. PubMed: 18243434.
8. Evans TG, McElrath MJ, Matthews T, Montefiori D, Weinhold K, et al. (2001) QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 19: 2080-2091. doi:10.1016/S0264-410X(00)00415-1. PubMed: 11228380.
9. Keefer MC, Wolff M, Gorse GJ, Graham BS, Corey L, et al. (1997) Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retrovir 13: 1163-1177. doi:10.1089/aid.1997.13.1163. PubMed: 9310283.
10. Boyle J, Eastman D, Millar C, Camuglia S, Cox J, et al. (2007) The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses. Vaccine 25: 2541-2544. doi:10.1016/j.vaccine.2006.12.018. PubMed: 17240491.
11. McKenzie A, Watt M, Gittleson C, (2010) ISCOMATRIX™ vaccines: Safety in human clinical studies. Hum Vaccin 6: 237-246. doi:10.4161/hv.6.3.10754.
12. Maraskovsky E, Schnurr M, Wilson NS, Robson NC, Boyle J, et al. (2009). ev Prophylactic Therapeutic Vaccines Using ISCOMATRIX Adj. 87: 371-376.
13. Pearse MJ, Drane D, (2004) ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses. Vaccine 22: 2391-2395. doi:10.1016/j.vaccine.2003.12.031. PubMed: 15193400.
14. Sanders MT, Brown LE, Deliyannis G, Pearse MJ, (2005) ISCOM-based vaccines: the second decade. Immunol Cell Biol 83: 119-128. doi:10.1111/j.1440-1711.2005.01319.x. PubMed: 15748208.
15. Morelli AB, Becher D, Koernig S, Silva A, Drane D, et al. (2012) ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol 61: 935-943. doi:10.1099/jmm.0.040857-0. PubMed: 22442293.
16. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, et al. (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc Natl Acad Sci U S A 101: 10697-10702. doi:10.1073/pnas.0403572101. PubMed: 15252201.
17. Maraskovsky E, Sjölander S, Drane DP, Schnurr M, Le TTT, et al. (2004) NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res 10: 2879-2890. doi:10.1158/1078-0432.CCR-03-0245. PubMed: 15102697.
18. Nicholaou T, Chen W, Davis ID, Jackson HM, Dimopoulos N, et al. (2011) Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™. Cancer Immunol Immunother 60: 1625-1637. doi:10.1007/s00262-011-1041-3. PubMed: 21698545.
19. Anderson JS, Hoy J, Hillman R, Barnden M, Eu B, et al. (2009) A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. J Acquir Immun Defic Syndr 52: 371-381. doi:10.1097/QAI.0b013e3181b7354c.
20. Frazer IH, Quinn M, Nicklin JL, Tan J, Perrin LC, et al. (2004) Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX™ adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23: 172-181. doi:10.1016/j.vaccine.2004.05.013. PubMed: 15531034.
21. Alving CR, Rao M, (2008) Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine 26: 3036-3045. doi:10.1016/j.vaccine.2007.12.002. PubMed: 18226433.
22. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, et al. (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316: 1628-1632. doi:10.1126/science.1138963. PubMed: 17569868.
23. Thompson BS, Chilton PM, Ward JR, Evans JT, Mitchell TC, (2005) The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J Leukoc Biol 78: 1273-1280. doi:10.1189/jlb.0305172. PubMed: 16204643.
24. RTS S, Clinical Trials Partnership, Agnandji ST, Lell B, Fernandes JF, et al (2012) A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 367: 2284-2295 doi:10.1056/NEJMoa1208394. PubMed: 23136909.
25. Lambrecht BN, Kool M, Willart MAM, Hammad H, (2009) Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 21: 23-29. doi:10.1016/j.coi.2009.01.004. PubMed: 19246182.
26. Marrack P, McKee AS, Munks MW, (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9: 287-293. doi:10.1038/nri2510. PubMed: 19247370.
27. Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, et al. (2005) Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 34: 226-236. doi:10.1111/j.1600-0684.2005.00120.x. PubMed: 16128917.
28. Vaine M, Wang S, Hackett A, Arthos J, Lu S, (2010) Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 28: 2999-3007. doi:10.1016/j.vaccine.2010.02.006. PubMed: 20170767.
29. Brown SA, Lockey TD, Slaughter C, Slobod KS, Surman S, et al. (2005) T cell epitope "hotspots" on the HIV Type 1 gp120 envelope protein overlap with tryptic fragments displayed by mass spectrometry. AIDS Res Hum Retrovir 21: 165-170. doi:10.1089/aid.2005.21.165. PubMed: 15725756.
30. Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T, et al. (2006) Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348: 341-353. doi:10.1016/j.virol.2005.12.029. PubMed: 16460776.
31. Pal R, Yu Q, Wang S, Kalyanaraman VS, Nair BC, et al. (2006) Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits. Vaccine 24: 1225-1234. doi:10.1016/j.vaccine.2005.07.112. PubMed: 16219399.
32. Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, et al. (2006) Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 346: 151-168. doi:10.1016/j.virol.2005.10.038. PubMed: 16325880.
33. Guy B, (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5: 505-517. doi:10.1038/nrmicro1681. PubMed: 17558426.
34. Luheshi G, Rothwell N, (1996) Cytokines and fever. Int Arch Allergy Immunol 109: 301-307. doi:10.1159/000237256. PubMed: 8634513.
35. Ogilvie AC, Hack CE, Wagstaff J, van Mierlo GJ, Erenberg AJ, et al. (1996) IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer. J Immunol 156: 389-394. PubMed: 8598489.
36. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, et al. (2001) Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14: 705-714. doi:10.1016/S1074-7613(01)00151-0. PubMed: 11420041.
37. Jones SA, (2005) Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 175: 3463-3468. PubMed: 16148087.
38. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C, (2003) IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 24: 25-29. doi:10.1016/S1471-4906(02)00013-3. PubMed: 12495721.
39. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, et al. (2000) The neutrophil as a cellular source of chemokines. Immunol Rev 177: 195-203. doi:10.1034/j.1600-065X.2000.17706.x. PubMed: 11138776.
40. Sjölander A, van't Land B, Lövgren Bengtsson K, (1997) Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol 177: 69-76. doi:10.1006/cimm.1997.1088. PubMed: 9140097.
41. Cassatella MA, (1995) The production of cytokines by polymorphonuclear neutrophils. Immunol Today 16: 21-26. doi:10.1016/0167-5699(95)80066-2. PubMed: 7880385.
42. Drane D, Maraskovsky E, Gibson R, Mitchell S, Barnden M, et al. (2009) Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine. Hum Vaccin 5: 151-157. doi:10.4161/hv.5.3.6614. PubMed: 19246990.
43. Sjölander A, Drane D, Maraskovsky E, Scheerlinck JP, Suhrbier A, et al. (2001) Immune responses to ISCOM formulations in animal and primate models. Vaccine 19: 2661-2665. doi:10.1016/S0264-410X(00)00497-7. PubMed: 11257406.
44. Yamashiro S, Kamohara H, Yoshimura T, (1999) MCP-1 is selectively expressed in the late phase by cytokine-stimulated human neutrophils: TNF-alpha plays a role in maximal MCP-1 mRNA expression. J Leukoc Biol 65: 671-679. PubMed: 10331497.
45. Wilson NS, Yang B, Morelli AB, Koernig S, Yang A, et al. (2011) ISCOMATRIX vaccines mediate CD8& plus; T-cell cross-priming by a MyD88-dependent signaling pathway. 1-13.
46. Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, et al. (2011) ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol 187: 55-63. doi:10.4049/jimmunol.1004114. PubMed: 21613613.
47. Sunderkötter C, (2009) Vasculitis of small blood vessels--some riddles about IgA and about the complexity of transmigration. Exp Dermatol 18: 91-96. doi:10.1111/j.1600-0625.2008.00791.x. PubMed: 18803657.